文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

刚果(金)东部Xpert检出的利福平耐药对耐多药结核预测价值欠佳

Xpert Mycobacterium tuberculosis/Rifampicin-Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该横断面研究纳入刚果(金)东部353例成人肺结核患者,以MTBDRplus为对照,评估Xpert检出的利福平耐药对耐多药结核的预测价值。Xpert对利福平耐药的敏感性为100.0%,但对耐多药结核的阳性预测值仅61.6%,提示在该高危人群中Xpert不宜单独作为耐多药结核的替代标志。

要点

  • Xpert对利福平耐药敏感性高,但对耐多药结核阳性预测值仅61.6%。
  • Xpert检出的利福平耐药菌株中仅61.6%合并MTBDRplus检出的异烟肼耐药。
  • 该地区应同时进行异烟肼和利福平耐药检测以确诊耐多药结核。

核心结论

  • 在该耐多药结核高危人群中,Xpert检出的利福平耐药对耐多药结核的阳性预测值低,应全面检测异烟肼和利福平耐药。

研究设计与样本

  • 配对留取痰标本分别进行涂片镜检和MTBDRplus检测,Xpert检测在镜检后剩余标本有试剂盒时进行。

主要发现

  • 353例中193例(54.7%)为既往治疗者,224例(63.5%)MTBDRplus结核阳性。
  • 224例中43例(19.2%)为利福平单耐药,11例(4.9%)为异烟肼单耐药,53例(23.7%)为耐多药结核,117例(52.2%)为利福平和异烟肼敏感。
  • MTBDRplus检出利福平耐药的96份样本中,53份(55.2%)为耐多药结核。
  • 179份(50.7%)标本进行了Xpert检测,其中163份(91.1%)结核阳性,73份(44.8%)利福平耐药。
  • Xpert检出的73株利福平耐药菌株中,仅45株(61.6%)经MTBDRplus检出合并异烟肼耐药。

临床怎么用

  • 在该地区,Xpert检出利福平耐药不能直接等同于耐多药结核,应补充异烟肼耐药检测。
  • 对耐多药结核高危患者,应同时进行异烟肼和利福平的全面耐药检测。

局限性

  • Xpert检测仅在部分标本(179/353,50.7%)中进行,可能影响结果代表性。
  • 本研究为横断面设计,未报告随访或临床结局数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rifampicin (RIF) resistance is highly correlated with isoniazid (INH) resistance and used as proxy for multidrug-resistant tuberculosis (MDR-TB). Using MTBDRplus as a comparator, we evaluated the predictive value of Xpert MTB/RIF (Xpert)-detected RIF resistance for MDR-TB in eastern Democratic Republic of the Congo (DRC). METHODS: We conducted a cross-sectional study involving data from new or retreatment pulmonary adult TB cases evaluated between July 2013 and December 2016. Separate, paired sputa for smear microscopy and MTBDRplus were collected. Xpert testing was performed subject to the availability of Xpert cartridges on sample remnants after microscopy. RESULTS: Among 353 patients, 193 (54.7%) were previously treated and 224 (63.5%) were MTBDRplus TB positive. Of the 224, 43 (19.2%) were RIF monoresistant, 11 (4.9%) were INH monoresistant, 53 (23.7%) had MDR-TB, and 117 (52.2%) were RIF and INH susceptible. Overall, among the 96 samples detected by MTBDRplus as RIF resistant, 53 (55.2%) had MDR-TB. Xpert testing was performed in 179 (50.7%) specimens; among these, 163 (91.1%) were TB positive and 73 (44.8%) RIF resistant. Only 45/73 (61.6%) Xpert-identified RIF-resistant isolates had concomitant MTBDRplus-detected INH resistance. Xpert had a sensitivity of 100.0% (95% CI, 92.1-100.0) for detecting RIF resistance but a positive-predictive value of only 61.6% (95% CI, 49.5-72.8) for MDR-TB. The most frequent mutations associated with RIF and INH resistance were S531L and S315T1, respectively. CONCLUSIONS: In this high-risk MDR-TB study population, Xpert had low positive-predictive value for the presence of MDR-TB. Comprehensive resistance testing for both INH and RIF should be performed in this setting.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bisimwa BC, Nachega JB, Warren RM, et al. Xpert Mycobacterium tuberculosis/Rifampicin-Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications. Clin Infect Dis. 2021. PMID: 32590841. doi:10.1093/cid/ciaa873

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。